{
    "organizations": [],
    "uuid": "9d61a4555bd254f29d31d444c9ab8b6eb678dc67",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acorda-therapeutics-sees-fy-2018-s/brief-acorda-therapeutics-sees-fy-2018-sales-330-mln-to-350-mln-for-ampyra-idUSL8N1P330I",
    "ord_in_thread": 0,
    "title": "BRIEF-Acorda Therapeutics Sees FY 2018 Sales $330 Mln To $350 Mln For AMPYRA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Acorda Therapeutics Inc:\n* ACORDA ANNOUNCES 2017 AMPYRA NET SALES AND PROVIDES 2018 FINANCIAL GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE\n* SEES FY 2018 SALES $330 MILLION TO $350 MILLION FOR AMPYRA\n* INBRIJA NDA RESUBMITTED IN DECEMBER 2017; INITIAL FDA RESPONSE EXPECTED IN FEBRUARY 2018\n* YEAR-END CASH BALANCE FOR 2018 IS PROJECTED TO BE OVER $300 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:28:00.000+02:00",
    "crawled": "2018-01-09T17:19:05.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "acorda",
        "therapeutic",
        "inc",
        "acorda",
        "announces",
        "ampyra",
        "net",
        "sale",
        "provides",
        "financial",
        "guidance",
        "morgan",
        "healthcare",
        "conference",
        "see",
        "fy",
        "sale",
        "million",
        "million",
        "ampyra",
        "inbrija",
        "nda",
        "resubmitted",
        "december",
        "initial",
        "fda",
        "response",
        "expected",
        "february",
        "cash",
        "balance",
        "projected",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}